CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Reports

We found 6378 result(s)

New at CADTH - February 2021

Last Updated: February 10, 2021
Result type: Reports
Product Line: New at CADTH

News and Events Canadian Medical Imaging Inventory CADTH has released the 2020 Canadian Medical Imaging Inventory (CMII). To view the full report and a summary of key findings, please visit www.cadth.ca/cmii. This is the third iteration of the CMII and it provides a clear picture of current practices and trends in the supply, distribution,...

New at CADTH - November 2020

Last Updated: November 12, 2020
Result type: Reports
Product Line: New at CADTH

News and Events CADTH’s 2020 Virtual Symposium: A Success! CADTH successfully wrapped up our first-ever virtual Symposium that was held on November 9 and 10, 2020. With more than 1,500 people in attendance, a diverse group of stakeholders gathered to discuss health care decision-making in an age of uncertainty, with health technology expert...

New at CADTH - April 2021

Last Updated: April 9, 2021
Result type: Reports
Product Line: New at CADTH

News and Events Call for Nominations Now Open for CADTH Board and Expert Committees
CADTH is seeking 15 new members from across the country for its Board of Directors and expert committees. Visit nominations.cadth.ca for details. The deadline to submit an application is Monday, April 26th, 2021. CADTH Recommends Gene Therapy fo...

New at CADTH - December 2020

Last Updated: December 8, 2020
Result type: Reports
Product Line: New at CADTH

News and Events CADTH Recommends First Gene Therapy Treatment for Rare Form of Childhood Vision Loss On November 16, CADTH recommended that Canada’s federal, provincial, and territorial drug plans (except Quebec) should reimburse, with conditions, voretigene neparvovec (also known as Luxturna and licensed by Novartis Pharmaceutical...

New at CADTH - January 2021

Last Updated: January 7, 2021
Result type: Reports
Product Line: New at CADTH

News and Events  “There’s Always Evidence…” — A Special Three-Part Webinar January and February 2021 Systematic reviews and meta-analyses are regarded as the gold standard for evidence, but they are not always readily available to inform a specific clinical, policy, or health management decision. In this special three-part webinar serie...

New at CADTH - March 2021

Last Updated: March 12, 2021
Result type: Reports
Product Line: New at CADTH

News and Events Call for Nominations CADTH is seeking nominations to its Board of Directors and Expert committees. We’re looking for 15 individuals with significant expertise in the Canadian health care system to join various committees. More information about the roles, the nomination process, honorarium, and time commitments is availabl...

Infliximab for the treatment of Crohn’s disease: A systematic review and cost-utility analysis

Last Updated: March 25, 2002
Result type: Reports

Cite as: Marshall J, Blackhouse G, Goeree R, Brazier N, Irvine E, Faulkner L, Dipchand C, O'Brien B. Infliximab for the Treatment of Crohn's Disease: A Systematic Review and Cost-Utility Analysis. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 2002. Technology report no 24. The Issue Crohn's disease (CD) is a c...

Economic analysis of Erythropoietin Use in Surgery

Last Updated: March 9, 1999
Result type: Reports

Cite as: Otten N. Economic evaluation of erythropoietin use in surgery. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 1998. The Issue The use of allogeneic (donor) blood transfusion is associated with risks such as the transmission of infectious diseases including HIV and Hepatitis B and C. The perioperativ...

Efficacy of rosiglitazone and pioglitazone compared to other anti-diabetic agents: systematic review and budget impact analysis

Last Updated: November 14, 2002
Result type: Reports

Technology Name Rosiglitazone (Avandia™) Pioglitazone (Actos™) Disease/Condition Diabetes mellitus is a serious disease characterized by an increase in blood glucose. It is estimated that more than one million Canadians over 12 years of age suffer from this condition. Type 2 diabetes is the most common form and affects 90% of persons with di...

Novel antipsychotics for agitation in dementia: A systematic review

Last Updated: March 31, 2003
Result type: Reports

Technology Name The novel antipsychotic drugs olanzapine (Zyprexa®) and risperidone (Risperdal®) Disease/Condition Dementia involves progressive loss of intellectual abilities such as language, comprehension, memory and learning, as well as changes in behaviour. This report focuses on agitation (restless movement with feelings of tension and ...